Publications by authors named "S K Forman"

Despite the success of the CD19xCD3 T cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed 267 adult patients with B-ALL treated with blinatumomab and used next generation sequencing to identify molecular alterations. Patients received blinatumomab for relapsed/refractory (R/R) disease (n=150), minimal residual disease (MRD+) (n=88), upfront as induction (n=10), or as consolidation in MRD- state (n=19).

View Article and Find Full Text PDF

Background: Sickle cell disease (SCD) confers neurological risks that contribute to cognitive and academic difficulties. Clinical guidelines state that cognition should be monitored using signaling questions. However, evidence is lacking regarding the extent to which signaling questions accurately identify children with cognitive issues.

View Article and Find Full Text PDF

Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.

View Article and Find Full Text PDF

Background: R-Glabridin is a major flavonoid of licorice (Glycyrrhiza glabra) root and known to modulate GABAA receptors, which are targets of many clinical hypnotics. However, R-glabridin hypnotic activity has not been reported in animals.

Methods: Inverted photomotor responses (IPMRs) were used to assess the hypnotic effects of natural R-glabridin and synthetic R/S-glabridin in wild-type zebrafish larvae and transgenic larvae lacking functional GABAA receptor β3 subunits (β30/0).

View Article and Find Full Text PDF
Article Synopsis
  • Ruxolitinib cream, shown to be safe and effective in a phase 3 study, has demonstrated its anti-inflammatory and itch-relieving properties in children aged 2-11 with mild to moderate atopic dermatitis (AD).
  • The study focused on assessing safety, tolerability, pharmacokinetics, and quality of life while using the cream at maximum levels over longer periods, with 29 children participating and applying the cream twice daily for 4 weeks, followed by individualized usage.
  • Results indicated that 31% of participants experienced treatment-related adverse events, but no severe health issues arose, and significant improvements in skin condition and quality of life were sustained for up to 52 weeks.
View Article and Find Full Text PDF